VerifyNow System, a point-of-care diagnostic, will be designed for use in clinical studies.
Accumetrics and Portola Pharmaceuticals will together develop and supply Accumetrics’ VerifyNow System and VerifyNowTests for use in clinical trials. The VerifyNow System is a point-of-care diagnostic for measuring platelet reactivity to multiple antiplatelet agents.
VerifyNow uses an automated analyzer with single-use, disposable assays. Accumetrics explains that whole-blood, closed-tube samples require no preparation for analysis. Platelet response is reported in five minutes or less, according to the firm.
Physicians can currently use the VerifyNow System to assess patients’ response to antiplatelet therapies on the market such as aspirin, P2Y12 inhibitors like sanofi aventis’ Plavix and Eli Lilly’s Effient, as well as GP IIb/IIIa inhibitors like Centocor’s ReoPro and Millennium Pharmaceuticals’ Integrilin.
It is also used by clinical researchers to measure the antiplatelet effect of drugs in development, according to Accumetrics and Portola. By incorporating the VerifyNow System in pharmaceutical clinical trials, data is generated to support the integration of platelet reactivity testing in the patient care pathway as new agents are introduced to the market